

SMi presents its 2014 masterclass on

## Quantitative Benefit – Risk Assessment for the New PSUR and Risk Minimisation

2nd  
**DEC**  
**2014**  
Central London

### Hosted by:

**Andrew Maguire**, Director, Global Epidemiology & Database Services

**Ignacio Mendes**, Director, Outcomes & Statistics,

**Nawab Qizilbash**, Head,

**OXON Epidemiology Ltd.**

### About the Masterclass:

The EMA expects MAHs to submit the new PSUR (PBRER) which marks a paradigm shift. The PSUR will change from being largely a document based online listings, narratives and simple sales-based incidence statistics to a benefit-risk tool with a much more statistical and quantitative approach to adverse event data, and including the incorporation of efficacy data. Risk minimisation measures have negative as well as positive consequences and these should be evaluated. The masterclass will provide attendees with the necessary exposure to approach the elements of benefit-risk analysis for the new PSUR in their company for new and old drugs and approaches to evaluate the positive and negative effects of risk minimisation measures.

### Key benefits of attending:

- Understand the requirements of the European GVP legislation for the New PSUR
- Appreciate the concepts behind quantitative BRA and why and when quantification is necessary
- Understand the process for undertaking BRA and the evidence and data requirements
- Describe the role of quantitative models in BRA and understand regulatory expectations including the current opinion of the European working groups
- Understand methodological options available and their pros and cons
- Appreciate the principles and practice of statistical BRA including the advantages and disadvantages of the principal methods
- Discuss how to implement/optimize BRA for the new PSUR in your company for old and new products, and learn what other companies are implementing
- Learn approaches to evaluate the negative and positive effects of risk minimisation measures.

In association with:



[www.smi-online.co.uk/ts05.asp](http://www.smi-online.co.uk/ts05.asp)

Register online and receive full information on all of SMi's conferences  
Alternatively fax your registration to +44 (0) 207 827 6067 or call +44 (0) 207 827 6067

GROUP DISCOUNTS AVAILABLE

MC389



# Quantitative Benefit – Risk Assessment for the New PSUR and Risk Minimisation

Register online and receive full information on all of SMI's conferences  
Alternatively fax your registration to +44 (0) 207 827 6067 or call +44 (0) 207 827 6066  
GROUP DISCOUNTS AVAILABLE

## MASTERCLASS AGENDA

09.00	Registration and Coffee	14.00	<ul style="list-style-type: none"><li>• Statistical methods</li><li>• Data requirements</li></ul>
09.30	Welcome and introductions		<ul style="list-style-type: none"><li>- Clinical efficacy/effectiveness data</li><li>- Safety data</li></ul>
09.45	Regulatory expectations for the new PSUR (PBRER) <ul style="list-style-type: none"><li>• Implementation</li><li>• Compliance</li><li>• System tracking</li><li>• Quality</li><li>• Auditability</li><li>• Links with RMP &amp; Signal detection</li></ul>	15.20	<ul style="list-style-type: none"><li>- Patient reported outcome efficacy data</li><li>- Meta-analysis of efficacy and safety data</li><li>- Statistical signal analysis</li><li>- Preferences and values</li></ul>
10.30	Understanding quantitative concepts (1)	15.20	Afternoon Tea
11.00	Morning Coffee	15.40	Discussion: Planning for the new PSUR for new and old products in your company
11.20	Understanding quantitative concepts (2)	16.15	Evaluation of the positive and negative effects of additional risk minimisation plans
12.00	Methodologies of benefit-risk assessment <ul style="list-style-type: none"><li>• Approaches with advantages and disadvantages</li></ul>	17.15	Review of the day
13.10	Lunch	17.30	End of Masterclass

### About your masterclass leaders:

**Andrew Maguire BSc MSc FSS, Director of Global Epidemiology & Database Services at OXON Epidemiology's Centre for Real World Secondary Data, London.** Andy is a statistical epidemiologist who has specialised in databases and quantitative benefit-risk analysis. He worked in the epidemiology departments of Pharmacia and Pfizer and subsequently at GPRD and THIN in the UK. Andy's last post was as Director of Epidemiology and Database Analytics for Europe for a US multinational scientific service provider. In this role he led a group of epidemiologists and programmers undertaking real world pharmacoepidemiological research using medical databases, epidemiological modelling as well as epidemiological and burden of disease support for the pharmaceutical sector. He has developed a benefit-risk model with ex-European regulators. He has published in Lancet, among many other journals. He has recently authored a book chapter on quantitative benefit risk analysis and has used BRA models in regulatory submissions (FDA and EMA).

**Ignacio Mendez VMD MPH, Director of HEOR & Field Analytics at OXON Epidemiology's Centre for Real World Field Studies, Madrid.** Ignacio has more than 17 years of experience in epidemiology, health economics, patient-reported outcomes and associated statistical methodologies. He specialises in the application and analysis of PROs and health economic measures in observational and PASS studies. He is currently a member of the ENCePP HTA task force of the EMA.

**Nawab Qizilbash MBChB MRCP(UK) BSc MSc DPhil(Oxon.) Clinical Epidemiologist & Head at OXON Epidemiology** and; Honorary Senior Lecturer in Pharmacoepidemiology, London School of Hygiene & Tropical Medicine; Honorary Consultant Geriatrician, Madrid; Member of Green-Templeton College, Oxford University and ENCePP-nominated 'EMA Expert'. Co-author of x5 Lancet, x1 JAMA and x3 BMJ publications in epidemiology, trials and meta-analysis. Chief editor of the internationally authored textbook: 'Evidence-based Dementia Practice' published by Blackwells, Oxford. Nawab was formerly: Director of Epidemiology & EBM at GlaxoSmithKline (1997-2005); Honorary Consultant Physician, Radcliffe Infirmary, Oxford; and chief editor of the Cochrane Dementia Group.

### About OXON



**OXON** is a consultancy and CRO based in London and Madrid that specialises in 'real world data' (www.oxonepi.com): Epidemiology (field and database studies and patient registries), Safety (PASS studies, statistical signal analysis, benefit-risk analysis, risk management), HEOR, Meta-analysis, development of concept protocols, and Evidence strategy for pre-and post-approval products. OXON provides the highest standards: an **ENCePP centre** of the European Medicines Agency with: a nominated '**EMA Expert**', membership of the Steering, Multi-data Source and HTA Groups, and Chair of the Data Integration Group; co-

authors of (x6) Lancets; an academic affiliation with the London School of Hygiene & Tropical Medicine; world renowned consultants with EMA and FDA experience: medical statistician, **Professor Stuart Pocock**. A 5-year alliance with the **10th largest global CRO** provides operational support for pan-European, Asian and Latin American projects.

# QUANTITATIVE BENEFIT – RISK ASSESSMENT FOR THE NEW PSUR AND RISK MINIMISATION

2nd December 2014, Central London

## 4 WAYS TO REGISTER

ONLINE [www.smi-online.co.uk/ts.05.asp](http://www.smi-online.co.uk/ts.05.asp)

FAX your booking form to +44 (0) 207 827 6067

PHONE on +44 (0) 207 827 6066

POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS

--	--

Unique Reference Number	
Our Reference	MC389

### DELEGATE DETAILS

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: \_\_\_\_\_ Forename: \_\_\_\_\_

Surname: \_\_\_\_\_

Job Title: \_\_\_\_\_

Department/Division: \_\_\_\_\_

Company/Organisation: \_\_\_\_\_

Email: \_\_\_\_\_

Company VAT Number: \_\_\_\_\_

Address: \_\_\_\_\_

\_\_\_\_\_

Town/City: \_\_\_\_\_

Post/Zip Code: \_\_\_\_\_ Country: \_\_\_\_\_

Direct Tel: \_\_\_\_\_ Direct Fax: \_\_\_\_\_

Mobile: \_\_\_\_\_

Switchboard: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

I agree to be bound by SMi's Terms and Conditions of Booking.

#### ACCOUNTS DEPT

Title: \_\_\_\_\_ Forename: \_\_\_\_\_

Surname: \_\_\_\_\_

Email: \_\_\_\_\_

Address (if different from above): \_\_\_\_\_

\_\_\_\_\_

Town/City: \_\_\_\_\_

Post/Zip Code: \_\_\_\_\_ Country: \_\_\_\_\_

Direct Tel: \_\_\_\_\_ Direct Fax: \_\_\_\_\_

### Terms and Conditions of Booking

**Payment:** If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings made within 7 days of the event require payment on booking.

**Substitutions/Name Changes:** If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not 'share' a place at an event. Please make separate bookings for each delegate.

**Cancellation:** If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted.

**Alterations:** It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.

**Data Protection:** The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here  we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager [databasemanager@smi-online.co.uk](mailto:databasemanager@smi-online.co.uk) or visit our website [www.smi-online.co.uk/updates](http://www.smi-online.co.uk/updates) quoting the URN as detailed above your address on the attached letter.

### MASTERCLASS PRICE

I would like to attend:	Fee	Total
<input type="checkbox"/> Masterclass:	£599.00 +VAT	£718.80

### FUTURE MASTERCLASSES

I would be interested in attending a Masterclass on the following topic or area:

\_\_\_\_\_

\_\_\_\_\_

### PAYMENT

Payment must be made to **SMi Group Ltd**, and received before the event, by one of the following methods **quoting reference MC389 and the delegate's name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment:**

**UK BACS** Sort Code **300009**, Account **00936418**

**Wire Transfer** Lloyds TSB Bank Plc, 39 Threadneedle Street, London, EC2R 8AU  
Swift (BIC): **LOYDGB21013**, Account **00936418**  
IBAN **GB48 LOYD 3000 0900 9364 18**

**Cheque** We can only accept Sterling cheques drawn on a UK bank.

**Credit Card**  Visa  MasterCard  American Express

All credit card payments will be subject to standard credit card charges.

Card No:

Valid From   /   Expiry Date   /

CVV Number     3 digit security on reverse of card, 4 digits for AMEX card

Cardholder's Name: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

I agree to be bound by SMi's Terms and Conditions of Booking.

Card Billing Address (if different from above): \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

### VENUE

Please contact me to book my hotel

Alternatively call us on +44 (0) 870 9090 711,  
email: [hotels@smi-online.co.uk](mailto:hotels@smi-online.co.uk) or fax +44 (0) 870 9090 712

### VAT

VAT at 20% is charged on the attendance fees for all delegates.